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Tolosana et al. have reported the results of a randomized study, which compared two procedures in preparation for implantation of pacemakers or cardioverter defibrillators (ICDs) in a small population of chronically anticoagulated patients at high risk of thrombo-embolic events. 1 One group was randomly assigned to continued oral anticoagulation (OAC) reduced to a target international normalized ratio (INR) near 2.0 for the procedure, and the other to temporary replacement of OAC by heparin, as recommended by current guidelines for high-risk patients. 2 -4 Considering the high proportion of chronically anticoagulated patients among the large population of cardiac device recipients, this is an important issue. In the recently published French PEOPLE registry, 5 11% of patients remained on OAC and nearly 20% received heparin at the time of procedure. This patient population is exposed to a dual risk during the critical period of re-arrangement of anticoagulation: (i) haemorrhage, particularly procedure-related pocket haematoma; and (ii) thrombo-embolism from under-anticoagulation during the peri-operative period. Furthermore, the choice of anticoagulation strategy directly influences the duration of hospitalization and overall cost of treatment. Thrombo-embolic risk
The haemorrhagic risk
The discontinuation and reintroduction of OAC raises the theoretical concern that it might cause a hypercoagulable state or a thrombotic rebound phenomenon. 6 An increase in the markers of activation of thrombosis by abrupt discontinuation of OAC has been observed, although it is not clear that it increases the risk of thrombo-embolic events. There are also theoretical concerns that, when OAC is reintroduced, a hypercoagulable state might be induced by suppression of proteins C and S. In practice, the thrombo-embolic risk of discontinuing OAC depends on individual indications and on the duration of OAC interruption. At highest risk are (i) patients with (a) mechanical mitral or tricuspid valve prostheses, (b) mechanical aortic valve prostheses with any risk factor, including atrial fibrillation (AF), previous thrombo-embolism, left ventricular ejection fraction ,0.30%, or disorders associated with hypercoagulation, (c) oldergeneration thrombogenic artificial valves, or (d) .1 mechanical valve; 10, 11 and (ii) patients in AF with mitral valve stenosis or histories of stroke, transient ischaemic attack, or systemic embolism. 9 The individual thrombo-embolic risk in AF specifically can be assessed, using the CHADS 2 score.
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There is general consensus with respect to the increase in thrombo-embolic risk incurred by the highest risk patients when OAC is discontinued without supplemental heparinization. Therefore, the latest American College of Cardiology/American Heart Association (ACC/AHA) professional guidelines have formulated the Class IIa, level of evidence B, recommendation ' . . . to start therapeutic doses of intravenous UFH when the INR falls below 2, to be stopped 4 to 6 hrs before the procedure, and restarted as early after surgery as bleeding stability allows, and continued until INR is again therapeutic with warfarin therapy'. 3 LMWH could be used instead of i.v. UFH 11 after discontinuation of warfarin, as suggested by a recent study of 650 patients, including 215 recipients of mechanical valves, in which the risk of thrombo-embolism was 0.62%, and major haemorrhages 0.95%.
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Less strict recommendations have been formulated for lower risk patients, which allow a temporary interruption of OAC without heparin substitution. For example, the ACC/AHA guidelines for management of patients with heart valve disease have formulated the following Class IIA, level of evidence B indication: 'In patients with low risk of thrombosis, defined as those with bileaflet mechanical aortic valve with no risk factors, it is recommended that warfarin be stopped 48 to 72 hrs before the procedure and restarted within 24 hrs after the procedure. Heparin is usually unnecessary'. 4 Similarly, the ACC/AHA/European Society of Cardiology guidelines for the management of patients with AF have issued a Class IIa, level of evidence C recommendation 'In patients with AF who do not have mechanical prosthetic heart valves, it is reasonable to interrupt anticoagulation for up to 1 week without substituting heparin for surgical or diagnostic procedures that carry a risk of bleeding', and a Class IIb, level of evidence C recommendation 'When surgical procedures require interruption of oral anticoagulant therapy for longer than 1 week in high-risk patients, unfractionated heparin may be administered or LMWH by subcutaneous injection, although the efficacy of these alternatives in uncertain'. 9 It is, however, noteworthy that these recommendations are based on expert consensus, and that the amount of clinical evidence remains small. In summary, the current recommendations offer two choices: (i) in high-risk patients, discontinuation of OAC and temporary anticoagulation with heparin, UFH, or LMWH; or (ii) in low-risk patients, discontinuation of OAC for 72 h in the presence of valve disease, 2 However, the strategy of continuing OAC significantly decreased the mean duration of hospitalization from 5.5+2 to 3.2+3 days (P , 0.0001). While these observations are of high interest, they cannot be universally applied, and must be interpreted with particular consideration of the short half-life of the vitamin K antagonist used in this trial (acenocoumarol), which differs markedly from that of warfarin, generally used in other countries.
Whether similar results would have been observed with warfarin is uncertain. Furthermore, the data pertaining to duration of hospitalization and putative health care cost savings must be interpreted as a function of each country's health care system, and might not be directly applicable to regions other than Catalonia or Spain. The 4.3-day mean duration of hospitalization seems relatively long for the type of procedure studied. Finally, the application of these results is limited to the implantation of pacemakers and ICDs, associated with an intermediate risk of haemorrhage, and does not extend to cardiac or non-cardiac operations associated with a higher haemorrhagic risk.
Since the haemorrhagic risk associated with pacemaker or ICD implantation procedures performed during anticoagulation is relatively low, it appears logical to favour the simplest and least expensive strategy. The study by Tolosona et al. suggests that, in a majority of high-risk patients, continuing OAC in lower doses is safe and cost-effective. We believe that this management strategy could be included in upcoming practice guidelines.
